Summary
CYP2C9 inhibitors are compounds that reduce the activity of the CYP2C9 enzyme, which can reduce drug metabolism, potentially impacting the effects of drug therapy.
CYP2C9 is a cytochrome P450 (CYP) enzyme found primarily in the liver and minorly in the intestines. It is involved in the metabolism of any medications that are CYP2C9 substrates, which includes many widely used medications.[1] CYP2C9 inhibitors can reduce the body’s metabolism of these medications.
The table below outlines some of the most common or clinically relevant CYP2C9 inhibitors.[1][2][3] Importantly, this list is not exhaustive.
| CYP2C9 Inhibitors |
|---|
| Amiodarone |
| Capecitabine |
| Fluconazole |
| Fluvastatin |
| Fluvoxamine |
| Metronidazole |
| Miconazole |
| Sulfamethoxazole |
| Voriconazole |
References
- ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
- ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
- ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)